Introduction
Diazoxide, a non-diuretic benzothiadiazine vasodilator (Naylor et al., 1968; Schmitt et al., 1968) has recently been reintroduced into the long-term therapy of severe hypertension because of its effectiveness despite its many side effects (Finnerty, 1968; Pohl and Thurston, 1971; .
The characteristics and management of reduction in free water clearance by the kidneys (Pohl et al., 1972 b) , renal sodium retention , and hyperglycaemia (Dollery et al., 1962; Wolff, 1964; Pohl and Thurston, 1971) have been well documented. Extrapyramidal side effects have not so far been attributed to diazoxide. During the acute and chronic management of 100 severely hypertensive patients with diazoxide (Pohl et al., 1972 c) and there was no alteration in muscle tone or tendon reflexes. He was given an intramuscular injection of 10 mg diazepam and his symptoms settled within 24 hours. Diazoxide and propranolol were continued in undiminished dosage, and over a period of three years there has been no recurrence of symptoms.
Case 6.-A woman aged 33 presented with uncontrolled hypertension (blood pressure 200/150 mm Hg) and renal failure (creatinine clearance 5-6 ml/min). Her blood pressure was controlled with oral diazoxide 100 mg three times a day. Her symptoms of severe headache and dyspnoea were abolished and her renal function began to improve. Two weeks later she became fearful and agitated with the rapid development of trismus and oculogyrus. On emination she was agitated and tremulous, her eyes were fixed in conjugate upward deviation and she had difficulty in opening her mouth which fluctuated from moment to moment. Power and tone in the limbs were normal, and while the tendon reflexes were exaggerated the plantar responses were flexor. Procyclidine 10 mg intravenously was given and within 15 minutes she had returned to normal. Diazoxide was discontinued and she was maintained on an oral dose of procyclidine for a further three days without recurrence of her neurological symptoms. Three weeks later when her blood pressure had again begun to rise diazoxide was introduced at a lower dosage of 50 mg three times a day and it was possible to maintain control of her blood pressure without the recurrence of any involuntary movement throughout a six-month period of observation.
Discussion
The existence of a category of hypertensives defined by general resistance to therapy and a very poor prognosis in the absence of adequate blood pressure control justified the reintroduction of diazoxide (Finnerty, 1968; Pohl and Thurston, 1971) which is effective in this situation but produces many side effects. The authors have gained wide experience in the long-term use of oral diazoxide, particularly in patients with impaired renal function (Thurston et al., 1973) , and found that side effects can be successfully controlled in most patients by careful attention to clinical detail. Those physicians who are prepared to use diazoxide as a long-term hypotensive agent require an up to-date knowledge of all the side effects likely to be encountered and how they can be managed. In this context some importance attaches to the claim that diazoxide causes extrapyramidal syndromes and that this is not a rare side effect. Our evidence for this claim rests, firstly, on the appearance of the syndrome after the introduction of diazoxide when no other drugs were administered (except low dose methyldopa-case 4) which are known to cause this effect, and, secondly, on the relation to dosage and likelihood of accumulation of this drug and its disappearance when the diazoxide dosage could either be diminished or stopped. We would attach particular importance to case 2 where the calculated free diazoxide serum levels showed a sharp peak (see graph) which coincided with the onset of a severe Parkinsonian syndrome. The syndrome resolved with the fall of the free diazoxide level. Diazoxide accumulates in renal failure (J. E. F. Pohl, H. Thurston, and J. D. Swales, unpublished observations) and it is likely the diazoxide levels in cases 3 and 4 were high, though no measurements were made. Though some of the cases in our hypertensive series who showed extrapyramidal symptoms on diazoxide were also receiving methyldopa, which could provide an alternative explanation, there is a higher mean serum diazoxide level in the patients requiring treatment of their extrapyranidcl symptoms ( 
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Total serum diazoxide levels (dotted line) and estimated free diazoxide levels (solid line) in case 2. Free diazoxide level was taken to be 9 % of total serum diazoxide with a ma2ximum binding capacity of 16 mg per 5 g of albumin per 100 ml (Sellers and Koch-Weser, 1969 Patients were bled one to two hours after the mid-day dose and had stable diazoxide levels on long-term therapy. The serum diazoxide levels were measured by extraction with ethyl acetate and spectrophotometric determination of absorbence at 280 mU (Symchowicz et al., 1967) .
